{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:59:17Z","timestamp":1790035157358,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Basic and Applied Basic Research Foundation of Guangdong Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05253-5","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:55:03Z","timestamp":1774515303000},"page":"13405-13415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vigilance for drug safety of darolutamide in the cancer therapies: a disproportionality analysis from the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"399","author":[{"given":"Zhenquan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiewen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"5253_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000519861","volume":"100","author":"V Achard","year":"2021","unstructured":"Achard V, Putora PM, Omlin A, Zilli T, Fischer S (2021) Metastatic prostate cancer: treatment options. Oncology 100:48\u201359","journal-title":"Oncology"},{"key":"5253_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1470-2045(24)00737-X","volume":"26","author":"H Bonnefoi","year":"2025","unstructured":"Bonnefoi H, Lerebours F, Pulido M, Arnedos M, Tredan O, Dalenc F, Guiu S, Teixeira L, Mollon D, Levy C et al (2025) Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial. Lancet Oncol 26:355\u2013366","journal-title":"Lancet Oncol"},{"key":"5253_CR3","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1365-2125.2011.04009.x","volume":"72","author":"F Chavant","year":"2011","unstructured":"Chavant F, Favreli\u00e8re S, Lafay-Chebassier C, Plazanet C, P\u00e9rault-Pochat MC (2011) Memory disorders associated with consumption of drugs: updating through a case\/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol 72:898\u2013904","journal-title":"Br J Clin Pharmacol"},{"key":"5253_CR4","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela Teuvo L, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I et al (2019) Darolutamide in nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 380:1235\u20131246","journal-title":"N Engl J Med"},{"key":"5253_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113258","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Shore ND, Smith M, Ramos R, Jones R, Niegisch G, Vjaters E, Wang Y, Srinivasan S, Sarapohja T et al (2023) Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2023.113258","journal-title":"Eur J Cancer"},{"key":"5253_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/clinem\/dgae417","volume":"100","author":"JA-O Huang","year":"2024","unstructured":"Huang JA-O, Su A, Yang J, Zhuang WA-O, Li ZSA-O (2024) Postmarketing safety concerns of teprotumumab: a real-world pharmacovigilance assessment. J Clin Endocrinol Metab 100:159\u2013165","journal-title":"J Clin Endocrinol Metab"},{"key":"5253_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/clinem\/dgae417","volume":"110","author":"J Huang","year":"2025","unstructured":"Huang J, Su A, Yang J, Zhuang W, Li Z Sr. (2025a) Postmarketing safety concerns of teprotumumab: a real-world pharmacovigilance assessment. J Clin Endocrinol Metab 110:159\u2013165","journal-title":"J Clin Endocrinol Metab"},{"key":"5253_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/15579883251346819","volume":"19","author":"L Huang","year":"2025","unstructured":"Huang L, He W, Guo Y (2025b) From androgen deprivation to precision therapy: a bibliometric review of global research trends (2008-2023). Am J Mens Health 19:15579883251346819","journal-title":"Am J Mens Health"},{"key":"5253_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41391-023-00740-9","volume":"27","author":"RH Jones","year":"2024","unstructured":"Jones RH, Fizazi K, James ND, Tammela TL, Matsubara N, Priou F, Beuzeboc P, Lesimple T, Bono P, Kataja V et al (2024) Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 27:786\u2013789","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5253_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0335459","volume":"20","author":"J Lee","year":"2025","unstructured":"Lee J, Song M, Leem S, Kim J-Y, Chung BI, Shim SR, Kim JH (2025) Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data. PLoS One 20:e0335459","journal-title":"PLoS One"},{"key":"5253_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2387317","author":"X Lin","year":"2025","unstructured":"Lin X, Yimin Z, Hongyan H, Wei Z, Wu L (2025) Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2024.2387317","journal-title":"Expert Opin Drug Saf"},{"key":"5253_CR12","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A et al (2024) Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol 42:4271\u20134281","journal-title":"J Clin Oncol"},{"key":"5253_CR13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14656566.2017.1329820","volume":"18","author":"ND Shore","year":"2017","unstructured":"Shore ND (2017) Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother 18:945\u2013952","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"5253_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/oncolo\/oyae019","volume":"29","author":"ND Shore","year":"2024","unstructured":"Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS et al (2024) Extended safety and tolerability of darolutamide for nonmetastatic castration-resistant prostate cancer and adverse event time course in ARAMIS. Oncologist 29(7):581\u2013588","journal-title":"Oncologist"},{"issue":"1","key":"5253_CR15","first-page":"10","volume":"75","author":"RA-O Siegel","year":"2025","unstructured":"Siegel RA-O, Kratzer TA-O, Giaquinto AA-O, Sung HA-O, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"key":"5253_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"R Smith Matthew","year":"2022","unstructured":"Smith Matthew R, Hussain M, Saad F, Fizazi K, Sternberg Cora N, Crawford ED, Kopyltsov E, Park Chandler H, Alekseev B, Montesa-Pino \u00c1 et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386:1132\u20131142","journal-title":"N Engl J Med"},{"key":"5253_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/00498254.2020.1723038","volume":"50","author":"P Taavitsainen","year":"2020","unstructured":"Taavitsainen P, Hille G, Timo K, Marja K, Chira M, Olaf P, Michael N, Steffen S, Wiebke J, Koskinen M (2020) Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats. Xenobiotica 50:967\u2013979","journal-title":"Xenobiotica"},{"key":"5253_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322378","volume":"20","author":"F Tan","year":"2025","unstructured":"Tan F, Li Y, Xia H, Yin W (2025a) Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases. PLoS One 20:e0322378","journal-title":"PLoS One"},{"key":"5253_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/andr.13668","volume":"13","author":"H Tan","year":"2025","unstructured":"Tan H, Luo L, Li W, Lan W, Chen Y, Huang G, Yang J, Xi X (2025b) A pharmacovigilance study of drug-reduced male semen quality based on the Food and Drug Administration adverse event reporting system database. Andrology 13:217\u2013225","journal-title":"Andrology"},{"key":"5253_CR20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.23736\/S2724-6051.23.05304-1","volume":"75","author":"G Tema","year":"2023","unstructured":"Tema G, Lombardo R, Cicione A, Nacchia A, Gravina C, Franco A, Fiasconaro D, Sarcinelli L, Ghezzo N, Pastore A et al (2023) Adverse events related to darolutamide treatment: analysis of \u201creal life\u201d data from EudraVigilance and the Food and Drug Administration database entries. Minerva Urol Nephrol 75:600\u2013606","journal-title":"Minerva Urol Nephrol"},{"key":"5253_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P (2019) Treatment of advanced prostate cancer. Annu Rev Med 70:479\u2013499","journal-title":"Annu Rev Med"},{"key":"5253_CR22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 Update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86:164\u2013182","journal-title":"Eur Urol"},{"key":"5253_CR23","doi-asserted-by":"crossref","unstructured":"Wang, T., He, G., Xiong, W., and Huang, J. (2025a). Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database. Frontiers in Pharmacology Volume 16 - 2025.","DOI":"10.3389\/fphar.2025.1563238"},{"key":"5253_CR24","doi-asserted-by":"crossref","unstructured":"Wang, Z., Lang, Y., Liu, X., Wang, Y., and Shao, L. (2025b). Post-marketing safety surveillance of voclosporin: an observational, pharmacovigilance study leveraging faers database study on the safety of voclosporin. Frontiers in Pharmacology Volume 16 - 2025.","DOI":"10.3389\/fphar.2025.1506760"},{"key":"5253_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","volume":"18","author":"SCR Williams","year":"2023","unstructured":"Williams SCR, Mazibuko N, O\u2019Daly O, Zurth C, Patrick F, Kappeler C, Kuss I, Cole PE (2023) Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial. Target Oncol 18:403\u2013413","journal-title":"Target Oncol"},{"key":"5253_CR26","doi-asserted-by":"crossref","unstructured":"Xiao H, Qin T, Wen Y, Ai L, Chen N, Cao L, Wu L (2024) A 13-years pharmacovigilance analysis of novel hormonal agents in prostate cancer using the FDA adverse event reporting system database. Expert Opin Drug Safety :1\u201310","DOI":"10.1080\/14740338.2024.2442514"},{"key":"5253_CR27","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/ijc.70059","volume":"157","author":"J Zhu","year":"2025","unstructured":"Zhu J, Huo X, Li X, Yang Z, Huang Z, Wu J, Li S, Jiang J (2025) Severe cutaneous adverse reactions associated with novel antiandrogens: a disproportionality analysis of three databases. Int J Cancer 157:2589\u20132602","journal-title":"Int J Cancer"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05253-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:43:35Z","timestamp":1783907015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05253-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5253"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05253-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The pharmacovigilance study under investigation employed a publicly accessible database comprising spontaneous reports. Given that the data were deidentified, the requirement for ethical approval was deemed unnecessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}